Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Adam Harvey, PhD

Clinical Scientist
Ferring Pharmaceuticals

Disclosure(s): Ferring Pharmaceuticals: Employment

Poster(s):

236 - Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
522 - Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET